1. Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma
- Author
-
Paul M. Barr, Thomas D. Rodgers, Andrea Baran, Carla Casulo, Clive S. Zent, AnnaLynn M. Williams, Patrick M. Reagan, Andrew G. Evans, and Jonathan W. Friedberg
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Antineoplastic Agents ,Disease course ,03 medical and health sciences ,Phosphatidylinositol 3-Kinases ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,In patient ,Adverse effect ,PI3K/AKT/mTOR pathway ,Retrospective Studies ,business.industry ,Lymphoma, Non-Hodgkin ,fungi ,food and beverages ,Hematology ,Leukemia, Lymphocytic, Chronic, B-Cell ,030220 oncology & carcinogenesis ,Toxicity ,Hodgkin lymphoma ,Phosphatidylinositol 3-Kinase ,business ,Idelalisib ,030215 immunology - Abstract
Phosphoinositide-3-kinase (PI3K) inhibitors have efficacy in lymphoid malignancies; however, inflammatory and infectious toxicities can compromise the treatment course. An improved understanding of these toxicities will guide clinical use and further development. We evaluated the occurrence of treatment-related adverse events (AEs) in a retrospective review of 79 patients treated in standard fashion with PI3K inhibitor monotherapy or with anti-CD20 monoclonal antibodies or as part of a novel combination regimen. Patients treated with a novel combination were at a higher risk of developing a severe AE compared to those treated with standard therapy (HR 1.89, 95% CI 1.02, 3.49
- Published
- 2020